Tinea infections:
Tinea corporis/tinea cruris: Topical: Apply to affected and surrounding area(s) twice daily until clinical resolution, typically 1 to 4 weeks (Weinstein 2002; manufacturer’s labeling).
Tinea pedis (labeled use)/tinea manuum (off-label use):
Treatment: Topical: Apply to affected and surrounding area(s) twice daily until 1 week after clinical resolution, typically for 4 weeks total (Weinstein 2002; manufacturer’s labeling).
Prevention (tinea pedis only): Topical: Apply once or twice daily.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
(For additional information see "Tolnaftate: Pediatric drug information")
Tinea pedis:
Treatment: Children ≥2 years and Adolescents: Topical: Apply twice daily for 4 weeks
Prevention: Children ≥2 years and Adolescents: Topical: Apply once or twice daily.
Tinea corporis, treatment: Children ≥2 years and Adolescents: Topical: Apply twice daily for 4 weeks.
Tinea cruris, treatment: Children ≥2 years and Adolescents: Topical: Apply twice daily for 2 weeks.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
Refer to adult dosing.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Aerosol, External:
Tinactin: 1% (150 g [DSC])
Aerosol Powder, External:
LamISIL AF Defense: 1% (133 g [DSC])
Tinactin: 1% (133 g)
Tinactin Deodorant: 1% (133 g)
Cream, External:
Antifungal (Tolnaftate): 1% (14.18 g) [odorless]
Fungi-Guard: 1% (15 g)
Fungoid-D: 1% (113 g [DSC]) [contains cetyl alcohol, methylparaben, propylene glycol, propylparaben, trolamine (triethanolamine)]
Tinactin: 1% (15 g, 30 g)
Generic: 1% (14 g, 14.18 g, 15 g, 20 g, 28 g, 28.3 g, 30 g)
Powder, External:
Anti-Fungal: 1% (45 g)
Podactin: 1% (45 g)
Generic: 1% (45 g)
Solution, External:
Dr Gs Clear Nail: 1% (18 mL) [contains propylene glycol]
Formula 3 The Treatment: 1% (15 mL) [contains butylparaben, methylparaben, propylparaben, sesame oil]
Formula 7 The Solution: 1% (15 g) [contains disodium edta]
Micotrin AL: 1% (30 mL) [contains benzyl alcohol]
Mycocide Clinical NS: 1% (30 mL) [contains propylene glycol]
Mycozyl AL: 1% (30 mL) [contains benzyl alcohol]
Tinaspore: 1% (10 mL)
May be product dependent
Topical: For external use only; avoid contact with eyes. Wash and dry affected area before drug application. For tinea pedis, also apply to spaces between the toes.
Aerosol, aerosol powder: Shake well prior to use.
Topical: For external use only; avoid contact with eyes. Wash and dry affected area before drug application. For tinea pedis, also apply to spaces between the toes.
Aerosol, aerosol powder, solution: Shake well prior to use.
Treatment of tinea pedis, tinea cruris, tinea corporis; prevention of tinea pedis
Tinea manuum
Tinactin may be confused with Talacen
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Dermatologic: Contact dermatitis, pruritus, stinging of the skin
Local: Irritation
Concerns related to adverse effects:
• Irritation: Discontinue if sensitivity or irritation occurs.
Special populations:
• Pediatric: Not for self-medication (OTC use) in children <2 years of age.
Other warnings/precautions:
• Appropriate use: For topical use only; avoid contact with eyes. Apply to clean, dry skin. When used for self-medication (OTC use), contact health care provider if condition does not improve within 4 weeks.
Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).
None known.
There are no known significant interactions.
Distorts the hyphae and stunts mycelial growth in susceptible fungi
Onset of action: 24 to 72 hours
Cream (Tinactin External)
1% (per gram): $0.42
Cream (Tolnaftate External)
1% (per gram): $0.15 - $0.29
Powder (Tolnaftate External)
1% (per gram): $0.06
Solution (Formula 3 The Treatment External)
1% (per mL): $1.08
Solution (Formula 7 The Solution External)
1% (per gram): $1.36
Solution (Micotrin AL External)
1% (per mL): $75.00
Solution (Mycozyl AL External)
1% (per mL): $75.00
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
